SRR35579825
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.520
- PROTEIN_SECRETION+0.390
- ANDROGEN_RESPONSE+0.340
- HEME_METABOLISM+0.280
- BILE_ACID_METABOLISM+0.270
- COAGULATION+0.250
- ADIPOGENESIS+0.230
- OXIDATIVE_PHOSPHORYLATION+0.230
- TNFA_SIGNALING_VIA_NFKB+0.220
- XENOBIOTIC_METABOLISM+0.220
Top 10 suppressed
- E2F_TARGETS-0.620
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V2-0.540
- MITOTIC_SPINDLE-0.380
- NOTCH_SIGNALING-0.290
- MYC_TARGETS_V1-0.280
- DNA_REPAIR-0.230
- GLYCOLYSIS-0.220
- WNT_BETA_CATENIN_SIGNALING-0.190
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG968 | — | — | 0.827 |
| 2 | TCGA-73-4677-01A-01R-1206-07 | — | cohortA2 | 0.817 |
| 3 | SRR8613737 | — | F | 0.805 |
| 4 | SRR8518337 | — | F | 0.789 |
| 5 | TCGA-FD-A6TI-01A-11R-A32O-07 | — | — | 0.787 |
| 6 | TCGA-67-3774-01A-01R-0946-07 | — | cohortA2 | 0.778 |
| 7 | TCGA-91-6849-01A-11R-1949-07 | — | cohortA2 | 0.769 |
| 8 | BS_2AR3AP0N | Ganglioglioma | — | 0.764 |
| 9 | BS_EHVYJAVA | pilocytic astrocytoma | — | 0.760 |
| 10 | TCGA-49-4501-01A-01R-1206-07 | — | cohortA1 | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.520 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.280 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |